CHEST Physician
-
Top reads from the CHEST journal portfolio – April 2025
Read these journal commentaries to explore studies on thrombus histopathology following PEA, endothelial biomarkers in pediatric sepsis to predict ARDS, and the role of high BMI in AATD-COPD.
-
Older patients have improved five-year survival for bilateral vs single lung transplant
Investigator, Haytham Elgharably, MD, discusses the practical implications of his recent research on bilateral lung transplant.
-
GLP-1 receptor agonists for managing OSA: Practical insights from an endocrinologist-sleep specialist
Brian Wojeck, MD, MPH, outlines the clinical considerations sleep medicine specialists will increasingly need to know to treat patients with obesity-related sleep apnea.
-
RSV vaccination boosts antibody titers in individuals with compromised immune systems
Rachana Krishna, MBBS, MSCR, said that while a recent study may not provide the ideal efficacy outcome data, the results are still helpful in counseling this patient population.
-
Sepsis order sets good for patients, hospital bottom lines
Automating the mundane components of care delivery allows clinicians to focus more on the nuances of individualized evaluation and personalized care.
-
Home high-flow nasal cannula therapy
Home high-flow nasal cannula therapy is a promising alternative form of respiratory support to NIV and CPAP. The treatment has been associated with a reduced number of acute exacerbations.
-
Strengthening more than just airways
Emerging research reveals that nutrition and exercise are two powerful yet underutilized tools in managing bronchiectasis.
-
Viscoelastic testing in sepsis-induced coagulopathy
SIC is a common ICU complication that clinicians are starting to identify in patients earlier through point-of-care viscoelastic testing such as rotational thromboelastometry and thromboelastography.
-
COPD program aims to close gaps in diagnosis and treatment
CHEST’s new Bridging Specialties®: Timely Diagnosis and Treatment for COPD program is focused on enhancing collaboration between PCPs and pulmonologists.
-
Novel obesity medications open door to new era in treatment of OSA
In December 2024, the FDA approved tirzepatide, a dual GIP and GLP-1 receptor agonist previously approved for type 2 diabetes and obesity, as the first prescription medication for adults with moderate to severe OSA and obesity.
